**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.**
Christoph Mronga, Department of Cardiology, Klinikum Oldenburg, University Hospital Oldenburg, Germany

**Main Body of the Abstract**
Introduction: Within recent years, specific treatments have been approved for the two most common types of systemic amyloidosis in Europe: tafamidis 61mg for systemic transthyretin amyloidosis (ATTR) with cardiac involvement and Daratumumab-CyBorD for systemic light-chain amyloidosis (AL). An amyloidosis clinic was established within the Oldenburg university hospital of internal medicine in oncology and hematology in October 2020. However, throughout our region with around two million inhabitants, ATTR patients in particular, have struggled to receive tafamidis, due to high treatment costs. Therefore, a clinic was also initiated in the department of cardiology in September 2022.
Methods: Analysis of amyloid patients seen and treated in both clinics between October 2020 until January 2024
Results: As the first clinic was primarily initiated in oncology in 2020 only six AL patients were treated. For 2021, a total of 25 patients were seen (22 AL, one ATTR, one SAA and one localized light-chain amyloidosis (locAL) patient). In 2022, a total of 30 patients presented with 20 AL, nine ATTR and one locAL patient. For 2023, at total of 60 patients were consulted with 31 AL, 22 ATTR, 3 SAA and two locAL patients. See figure below.
Overall, there are currently 34 AL patients being consulted with patients receiving daratumumab-based (n=14), IMID-based (n=4) or venetoclax-based (n=4) combinations and 23 ATTR patients either already receiving tafamidis (n=17) or still in work-up (e.g. concomitant gammopathy requiring cardiac biopsy).
Summary: Our clinics can provide modern therapies for amyloid patients within our region



**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.**
Christoph Mronga, Department of Cardiology, Klinikum Oldenburg, University Hospital Oldenburg, Germany

**Main Body of the Abstract**
**Introduction:** Within recent years, specific treatments have been approved for the two most common types of systemic amyloidosis in Europe: tafamidis 61mg for systemic transthyretin amyloidosis (ATTR) with cardiac involvement and Daratumumab-CyBorD for systemic light-chain amyloidosis (AL). An amyloidosis clinic was established within the Oldenburg university hospital of internal medicine in oncology and hematology in October 2020. However, throughout our region with around two million inhabitants, ATTR patients in particular, have struggled to receive tafamidis, due to high treatment costs. Therefore, a clinic was also initiated in the department of cardiology in September 2022.
**Methods:** Analysis of amyloid patients seen and treated in both clinics between October 2020 until January 2024
**Results:** As the first clinic was primarily initiated in oncology in 2020 only six AL patients were treated. For 2021, a total of 25 patients were seen (22 AL, one ATTR, one SAA and one localized light-chain amyloidosis (locAL) patient). In 2022, a total of 30 patients presented with 20 AL, nine ATTR and one locAL patient. For 2023, at total of 60 patients were consulted with 31 AL, 22 ATTR, 3 SAA and two locAL patients. See figure below.
Overall, there are currently 34 AL patients being consulted with patients receiving daratumumab-based (n=14), IMID-based (n=4) or venetoclax-based (n=4) combinations and 23 ATTR patients either already receiving tafamidis (n=17) or still in work-up (e.g. concomitant gammopathy requiring cardiac biopsy).
**Summary:** Our clinics can provide modern therapies for amyloid patients within our region



Establishing amyloidosis clinics at a university hospital in the Northwest of Germany PC141 (#498)

We invite you to attend the XIX International Symposium on Amyloidosis to be held in Rochester, MN.

This symposium is organized as a hybrid meeting (with the focus on in-person) held from Sunday, May 26 through Thursday, May 30, 2024.

Together with the ISA Board and members of Mayo Clinic, a very attractive scientific hybrid program is being planned. The program will cover a variety of types of systemic amyloidosis: ATTR (hereditary and wild-type), AL (light-chain), AA and less frequent forms. There will be key lectures, specific symposia including those company sponsored, oral presentations and poster sessions of accepted abstracts.

COURSE DESCRIPTION
This program will provide a comprehensive review of state-of-the-art education in systemic amyloidosis: basic science, pathophysiology, diagnosis, current and emerging treatments. Scientific presentations will include competitive oral and poster abstracts. The rapid evolution of scientific discovery and expanding treatment options has created tremendous interest in the field and this meeting will fill and important gap in educating scientists and clinicians.